Optherion’s Genetic Research in Dry
AMD
Featured in Forbes
Optherion, Inc. Completes $37 Million Start Up Financing
Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
About Optherion
Our Technology
Product Pipeline
Board of Directors
Management Team
